Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Inclusion Criteria

• •Histologically confirmed diagnosis of 1 of the following:
• •* Malignant extracranial solid tumor
• •* Recurrent or refractory disease
• •* Known bone marrow metastases\* allowed
• •* Imatinib mesylate-resistant Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), defined as M3 bone marrow in a patient who previously received imatinib mesylate-containing treatment regimen
• •* Imatinib mesylate-resistant Ph+ chronic myelogenous leukemia (CML), as defined by any of the following:
• •* Increasing WBC or platelet count while on imatinib mesylate therapy
• •* Lack of any cytogenetic response after an adequate duration of imatinib mesylate therapy, as defined by 1 of the following:
• •* Failed to achieve a complete hematologic response after completion of 3 months of imatinib mesylate treatment
• •* Failed to achieve a partial or complete cytogenetic response (i.e., ≤ 35% Ph+ cells) after 6 months of imatinib mesylate treatment
• •* Appearance of accelerated or blastic feature while on imatinib mesylate therapy
• •* Reappearance of Ph+ clones after an initial complete cytogenetic response to imatinib mesylate
• •* More than 30% increase in Ph+ cells in peripheral blood or bone marrow cytogenetics while on imatinib mesylate therapy
• •* Imatinib mesylate intolerance, as defined by development of adverse effects requiring discontinuation of imatinib mesylate therapy
• •Measurable disease (for patients with CML or ALL)
• •* Determined by hematologic, cytogenetic, and molecular studies for CML
• •* Determined by bone marrow blast percentage for ALL
• •Measurable or evaluable disease (for patients with solid tumors)
• •No known curative therapy or survival-prolonging therapy with an acceptable quality of life
• •No CNS solid tumors
• •* CNS-positive leukemia allowed
• •Karnofsky performance status (PS) ≥ 50% (for patients \> 10 years of age)
• •Lansky PS ≥ 50% (for patients ≤ 10 years of age)
• •No evidence of graft-vs-host disease
• •Solid tumors:
• •* Absolute neutrophil count ≥ 1,000/mm\^3 (750/mm\^3 if bone marrow infiltration)
• •* Platelet count ≥ 100,000/mm\^3 (transfusion independent) (50,000/mm\^3 if bone marrow infiltration)
• •* Hemoglobin ≥ 8.0 g/dL (red blood cell \[RBC\] transfusions allowed)
• •ALL/CML:
• •* Platelet count ≥ 20,000/mm\^3 (platelet transfusions allowed)
• •* Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)
• •Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine based on age, as follows:
• •* No greater than 0.6 mg/dL (1-23 months of age)
• •* No greater than 0.8 mg/dL (2- 5 years of age)
• •* No greater than 1.0 mg/dL (6-9 years of age)
• •* No greater than 1.2 mg/dL (10-12 years of age)
• •* No greater than 1.4 mg/dL (13 years of age and over \[female\])
• •* No greater than 1.5 mg/dL (13-15 years of age \[male\])
• •* No greater than 1.7 mg/dL (16 years of age and over \[male\])
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •ALT ≤ 110 U/L
• •Albumin ≥ 2 g/dL
• •Normal 12-lead EKG with corrected QTc \< 450 msec AND meets 1 of the following criteria:
• •* Shortening fraction normal
• •* Ejection fraction normal
• •No evidence of dyspnea at rest
• •No exercise intolerance
• •Pulse oximetry \> 94% if there is a clinical indication for determination
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No uncontrolled infection
• •No swallowing dysfunction that would prevent taking an oral or liquid medication
• •See Disease Characteristics
• •Recovered from prior chemotherapy, immunotherapy, or radiotherapy
• •No myelosuppressive chemotherapy within the past 3 weeks (6 weeks for nitrosoureas)
• •At least 7 days since prior growth factors
• •At least 14 days since prior pegfilgrastim
• •At least 7 days since prior biologic agents
• •At least 2 weeks since prior local small-port palliative radiotherapy
• •At least 3 months since prior total-body irradiation, craniospinal radiation, or radiation to ≥ 50% of the pelvis
• •At least 6 weeks since other prior substantial bone marrow radiation
• •At least 3 months since prior stem cell transplantation
• •Hydroxyurea cytoreduction for Ph+ leukemia allowed provided it is discontinued 24 hours before first dose of dasatinib
• •Prior intrathecal (IT) therapy allowed (for patients with CNS-positive leukemia)
• •Concurrent IT therapy comprising hydrocortisone, cytarabine, methotrexate, or cytarabine (liposomal) allowed (for patients with CNS-positive leukemia)
• •No other concurrent investigational drugs
• •No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy
• •No concurrent enzyme-inducing anticonvulsants, including any of the following:
• •* Phenytoin
• •* Phenobarbital
• •* Carbamazepine
• •* Felbamate
• •* Primdone
• •* Oxcarbazepine
• •No concurrent antithrombotic or antiplatelet agents, including any of the following:
• •* Warfarin
• •* Heparin
• •* Low-molecular weight heparin
• •* Aspirin
• •* Ibuprofen
• •* Other nonsteroidal anti-inflammatory drugs
• •No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, and voriconazole
• •No concurrent highly active antiretroviral treatment for HIV-positive patients